These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16541185)

  • 1. Abatacept.
    Vital EM; Emery P
    Drugs Today (Barc); 2006 Feb; 42(2):87-93. PubMed ID: 16541185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abatacept: a novel treatment for rheumatoid arthritis.
    Lundquist LM
    Expert Opin Pharmacother; 2007 Oct; 8(14):2371-9. PubMed ID: 17927490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
    Sherrer Y
    Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CTLA4-Ig (abatacept)].
    Harigai M
    Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Insight: abatacept for the treatment of rheumatoid arthritis.
    Ruderman EM; Pope RM
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):654-60. PubMed ID: 17133250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abatacept in the treatment of rheumatoid arthritis.
    Todd DJ; Costenbader KH; Weinblatt ME
    Int J Clin Pract; 2007 Mar; 61(3):494-500. PubMed ID: 17313619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
    Scheinfeld N
    J Dermatolog Treat; 2006; 17(4):229-34. PubMed ID: 16971318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of abatacept in rheumatoid arthritis.
    von Kempis J; Dudler J; Hasler P; Kyburz D; Tyndall A; Zufferey P; Villiger PM
    Swiss Med Wkly; 2012; 142():w13581. PubMed ID: 22581564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis.
    Barr C
    J Infus Nurs; 2007; 30(2):96-104; quiz 120. PubMed ID: 17413494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.
    Reynolds J; Shojania K; Marra CA
    Pharmacotherapy; 2007 Dec; 27(12):1693-701. PubMed ID: 18041889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
    Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
    J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
    N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of abatacept in patients with rheumatoid arthritis.
    Atzeni F; Sarzi-Puttini P; Mutti A; Bugatti S; Cavagna L; Caporali R
    Autoimmun Rev; 2013 Oct; 12(12):1115-7. PubMed ID: 23800448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation].
    Dejaco C; Duftner C; Wipfler E; Schirmer M
    Wien Med Wochenschr; 2009; 159(3-4):70-5. PubMed ID: 19247593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation.
    Konsta M; Rallis E; Karameris A; Stratigos A; Sfikakis PP; Iliopoulos A
    J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):257-8. PubMed ID: 22280512
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putting new disease-modifying antirheumatic drugs into perspective.
    Saseen JJ
    Pharmacotherapy; 2007 Dec; 27(12):1609-10. PubMed ID: 18041880
    [No Abstract]   [Full Text] [Related]  

  • 20. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.